Anika Therapeutics Inc（ANIK）财务数据ANIKAnika Therapeutics Inc

Anika Therapeutics Inc (ANIK) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is OEM Channel, accounting for 57.4% of total sales, equivalent to $18.70M. Another important revenue stream is Commercial Channel. Understanding this composition is critical for investors evaluating how ANIK navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Anika Therapeutics Inc maintains a gross margin of 65.15%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 10.69%, while the net margin is 10.15%. These profitability ratios, combined with a Return on Equity (ROE) of -2.19%, provide a clear picture of how effectively ANIK converts its operational activities into shareholder value.

In the context of the broader market, ANIK competes directly with industry leaders such as TMCI and OSUR. With a market capitalization of $272.95M, it holds a significant position in the sector. When comparing efficiency, ANIK's gross margin of 65.15% stands against TMCI's 78.47% and OSUR's 43.46%. Such benchmarking helps identify whether Anika Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Anika Therapeutics reported a revenue of $32.6 million in Q2 2026, a 17% year-over-year increase, with a gross margin of 65.15%, showing improving profitability. Despite some losses, the company is expected to achieve a net income of $0.02 EPS in the upcoming quarter, reflecting a turnaround in performance.